Cheplapharm to buy AstraZeneca’s heart failure and hypertension drugs for $400m

This article was originally published here

Under the deal, Cheplapharm will purchase Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide), which is marketed in around 70 countries across

The post Cheplapharm to buy AstraZeneca’s heart failure and hypertension drugs for $400m appeared first on Pharmaceutical Business review.